EP4536363A1 — Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
Assigned to Nikang Therapeutics Inc · Expires 2025-04-16 · 1y expired
What this patent protects
The present disclosure provides certain sulfamide derivatives that are cydin-dependent kinase 2 (CDK2) inhibitors of Formula (I) for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical compositions containing such compounds and processes fo…
USPTO Abstract
The present disclosure provides certain sulfamide derivatives that are cydin-dependent kinase 2 (CDK2) inhibitors of Formula (I) for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.